Posts by Sandra Ansanay-Alex
Terapet Launches FLASHVIVO to Enable Real-Time Verification in FLASH Therapy
Gevena-based start-up and CERN spinoff Terapet SA has announced the launch of FLASHVIVO, a new collaborative research and development project designed to tackle one of the most critical challenges facing the clinical adoption of FLASH radiotherapy: the lack of real-time, in vivo treatment verification under ultra-high dose rate conditions. FLASH radiotherapy has emerged as a…
Read MoreScientist To Founder
The Scientist to Founder event, organised by CERN, is taking place on 16 April 2026 at Prévessin (France) How do you turn scientific research into a company? Where’s the right place to start? And once you’ve started, how do you get your idea funded at the earliest stage? CERN’s Entrepreneurship team invites you to meet and…
Read MoreEcotrophelia
Ecotrophelia, powered by the Swiss Food and Nutrition Valley, is taking place on 17 April 2026 at HES-SO Valais Wallis Ecotrophelia Switzerland is the national student food innovation competition where multidisciplinary teams from Swiss universities develop and pitch sustainable, market-ready food products before an expert jury of industry and academic leaders. The winning team goes on…
Read MoreSMART Challenge
The SMART Challenge 2026 kicks off on 21 April 2026 —and it needs concrete, innovative ideas to make physical activity more accessible, more appealing, and above all… easier to incorporate into daily life. Are you an entrepreneur, a student, a healthcare professional, or simply someone with an impactful idea that needs to be tested in…
Read MoreFondation des HUG – Call For Projects
Thanks to the generous support of a private Geneva-based foundation, the Fondation privée des HUG is launching five new calls for projects in 2026, with a total funding envelope of CHF 10 million. This major initiative aims to support projects led by teams from the Geneva University Hospitals (HUG) and the Faculty of Medicine at…
Read MoreOculis Announces European Medicines Agency PRIME Designation for Privosegtor
Oculis Holding AG, based in canton of Vaud and Zug, has received a significant regulatory boost for its neuroprotective candidate Privosegtor, with the European Medicines Agency (EMA) granting the therapy Priority Medicines (PRIME) designation for the treatment of optic neuritis (ON). Optic neuritis is a rare and sight-threatening condition that can occur as a relapse…
Read MoreStarting up in Women’s Health
Starting up in Women’s Health is taking place on 23 April 2026 at Sitem-Insel in Bern Women’s health is entering a new era of innovation—driven by advances in gender medicine, digital technologies, and entrepreneurial potential. This seminar brings together experts from research, clinical practice, digital health, and venture capital to explore how scientific insights can be…
Read MoreAge Innovation Prize
Apply before 14 June 2026 for the Age Innovation Prize of the Institute for Ageing Research IAF in partnership with the Age-Stiftung. This Switzerland-wide competition promotes innovative ideas that deal with the challenges of age(ing). It honours innovative technological (AgeTech) and social projects that promote the independence, social inclusion, quality of life and health of…
Read MoreValorization Award 2026
Join the Knowledge Transfer UNIL CHUV for the VALORIZATION AWARD 2026 on 11 june 2026 at Biopôle Campus. This event will bring together experts and professionals from both the public and private sectors to share their insights, experiences, and perspectives on transforming research into tangible value. 🚀The programme includes:– Expert roundtable on financial support for…
Read MoreUsinnove Soft Opening
Microcity invites you to an exclusive soft opening of Usinnove on 28 April 2026 in Neuchâtel HLD – Human Lean Diagnostics and its Usinnove innovation center embody an ecosystem dedicated to human health, built on the canton’s unique technological heritage: micro- and nanofabrication, detection and sensing, automation, and digital analytics. The official opening of the…
Read More